corneat received the green light to conduct clinical trials on 10 patients with corneal blindness in 2020, said gilad litvin, corneat vision’s co-founder, cmo and the inventor of the implant itself. he said being present for the procedure was a surreal experience. “after years of hard work, seeing a colleague implant the corneat kpro with ease and witnessing a fellow human being regain his sight the following day was electrifying and emotionally moving, there were a lot of tears in the room.”
in addition to the nine other patients in line for the procedure in israel, corneat has its eyes focused firmly on the future with two more locations set to open in canada soon. another six sites, destined for france, the u.s. and the netherlands, are currently in various stages of approval. after initially tending to those most in need, the company hopes the procedure will become more widely available.
“our first trial includes blind patients who are not suitable candidates for, or have failed one or more corneal transplantations,” said almog aley-raz, corneat vision’s co-founder, ceo and vice-president of research and development. “given the visual performance of our device, the expected healing time and retention and the fact that it cannot carry disease, we plan to initiate a second study later this year with broader indications to approve our artificial cornea as a first line treatment, displacing the use of donor tissue used in full thickness corneal transplantations.”